YANFENG GAO

Dr. YANFENG GAO

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in eClinicalMedicine
Verified
Journal Article
Open access
YZYu-Miao Zhao
Yu-Miao Zhao
YSYao-Min Shang
Yao-Min Shang
WSWen-Bin Song
Wen-Bin Song
QLQing-Quan Li
Qing-Quan Li
HXHua Xie
Hua Xie
AXAi-Guo Xu
Ai-Guo Xu
The long-term pulmonary function and related physiological characteristics of COVID-19 survivors have not been studied in depth, thus many aspects are not understood. COVID-19 survivors were recruited for high resolution computed tomography (HRCT) of the thorax, lung function and serum levels of SARS-CoV-2 IgG antibody tests 3 months after discharge. The relationship between the clinical characteristics and the pulmonary function or CT scores were investigated. Fifty-five recovered patients participated in this study. SARS-CoV-2 infection related symptoms were detected in 35 of them and different degrees of radiological abnormalities were detected in 39 patients. Urea nitrogen concentration at admission was associated with the presence of CT abnormalities (P = 0.046, OR 7.149, 95% CI 1.038 to 49.216). Lung function abnormalities were detected in 14 patients and the measurement of D-dimer levels at admission may be useful for prediction of impaired diffusion defect (P = 0.031, OR 1.066, 95% CI 1.006 to 1.129). Of all the subjects, 47 of 55 patients tested positive for SARS-CoV-2 IgG in serum, among which the generation of Immunoglobulin G (IgG) antibody in female patients was stronger than male patients in infection rehabilitation phase. Radiological and physiological abnormalities were still found in a considerable proportion of COVID-19 survivors without critical cases 3 months after discharge. Higher level of D-dimer on admission could effectively predict impaired DLCO after 3 months discharge. It is necessary to follow up the COVID-19 patients to appropriately manage any persistent or emerging long-term sequelae. Key Scientific Research Projects of Henan Higher Education Institutions

10 August 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HCHao‐Nan Chang
Hao‐Nan Chang
BLBei‐Yuan Liu
Bei‐Yuan Liu
YQYun‐Kun Qi
Yun‐Kun Qi
YZYang Zhou
Yang Zhou
YCYan‐Ping Chen
Yan‐Ping Chen
YGYANFENG GAO
YANFENG GAO

1 August 2014 in Cancer Letters
Verified
Journal Article
Closed access
DWDong-Dong Wu
Dong-Dong Wu
YGYANFENG GAO
YANFENG GAO
YQYuanming Qi
Yuanming Qi
LCLixiang Chen
Lixiang Chen
YMYuanfang Ma
Yuanfang Ma
YLYanzhang Li
Yanzhang Li

24 August 2016 in Nature Communications
Verified
Journal Article
Open access
ZCZhen-Zhen Chen
Zhen-Zhen Chen
LHLan Huang
Lan Huang
YWYahong Wu
Yahong Wu
WZWen-Jie Zhai
Wen-Jie Zhai
PZPing-Ping Zhu
Ping-Ping Zhu
YGYANFENG GAO
YANFENG GAO
Liver cancer has a tendency to develop asymptomatically in patients, so most patients are diagnosed at a later stage. Accumulating evidence implicates that liver tumour-initiating cells (TICs) as being responsible for liver cancer initiation and recurrence. However, the molecular mechanism of liver TIC self-renewal is poorly understood. Here we discover that a long noncoding RNA (lncRNA) termed LncSox4 is highly expressed in hepatocellular carcinoma (HCC) tissues and in liver TICs. We find that LncSox4 is required for liver TIC self-renewal and tumour initiation. LncSox4 interacts with and recruits Stat3 to the Sox4 promoter to initiate the expression of Sox4, which is highly expressed in liver TICs and required for liver TIC self-renewal. The expression level of Sox4 correlates with HCC development, clinical severity and prognosis of patients. Altogether, we find that LncSox4 is highly expressed in liver TICs and is required for their self-renewal.

17 April 2012 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
CDChao Dai
Chao Dai
ZXZhaoqing Xu
Zhaoqing Xu
FHFei Huang
Fei Huang
ZYZhengkun Yu
Zhengkun Yu
YGYANFENG GAO
YANFENG GAO

1 January 2022 in Theranostics
Verified
Journal Article
Open access
GCGuanyu Chen
Guanyu Chen
WKWeirong Kang
Weirong Kang
WLWanqiong Li
Wanqiong Li
SCShaomeng Chen
Shaomeng Chen
YGYANFENG GAO
YANFENG GAO
The past few years has witnessed a booming market of protein and peptide drugs, owing to their superior efficiency and biocompatibility. Parenteral route is the most commonly employed method for protein and peptide drugs administration. However, short plasma half-life protein and peptide drugs requires repetitive injections and results in poor patient compliance. Oral delivery is a promising alternative but hindered by harsh gastrointestinal environment and defensive intestinal epithelial barriers. Therefore, designing suitable oral delivery systems for peptide and protein drugs has been a persistent challenge. This review summarizes the main challenges for oral protein and peptide drugs delivery and highlights the advanced formulation strategies to improve their oral bioavailability. More importantly, major intestinal cell types and available targeting receptors are introduced along with the potential strategies to target these cell types. We also described the multifunctional biomaterials which can be used to prepare oral carrier systems as well as to modulate the mucosal immune response. Understanding the emerging delivery strategies and challenges for protein and peptide drugs will surely inspire the production of promising oral delivery systems that serves therapeutic needs in clinical settings.